Galenika A.D.

An EMIS Company Report EMIS is a Euromoney Institutional Investor plc company USD 29.95 Industry: Pharmaceutical and Medicine Manufacturing Available in: English Format: PDF Download Most recent financial data: 2016 Buy full report

What’s included?

This report extracts all available information about this company from EMIS' database of company information. The Table of Contents on the right indicates the categories of information that will be included in your report upon purchase.

Download a sample report

Company Tear Sheet (locked content will be provided in the purchased report)

Contact Information

Batajnicki Drum Bb
Belgrade; Belgrade; Map
Postal Code: 11080

Tel: (+381 11) 307 10 , 307
Fax: (+381 11) 307 16



Company Description
Galenika, a state-controlled firm established in 1945, was the first company in former Yugoslavia to be acquired by a foreign partner.
ICN Pharmaceuticals, which acquired a 75% stake in the drug maker under a 1990 agreement, planned to use it as a platform for growth in eastern Europe.
Serbia's government took over the Belgrade plant of ICN Pharmaceuticals in February 1999, after the commercial court in Belgrade ruled that ICN held a 35% stake and not 75%. Galenika claimed a 25% share of the Serbian pharmaceuticals market in 2005, producing 36 out of the 100 best selling drugs in the country.
Serbia’s Privatisation Agency opened a privatisation tender for the company in December 2009 but it failed.
In June 2010, Galenika opened a EUR 50 million solid drugs plant in Zemun. A month later, the firm announced plans to open a representative office in Albania. As of 2017, the company is represented in Montenegro, Bosnia i Herzegovina, Russia and Macedonia.
NAICS Industry Classification
Basic Information
Key Executives
Ownership Details
Key Financial Highlights
Financial Performance Charts
Top Competitors

Financial Statements

Annual Statements

EMIS Credit Analytics

EMIS Benchmark Score

What this report allows you to do

EMIS company reports provide the data you need to make accurate assessments about businesses you are interested in.

Identify sales opportunities

  • Does the company match your target demographic?
  • Who are the key executives?

Conduct risk assessment

  • Is the company creditworthy?
  • Is it financially stable?

Carry out strategic research

  • Is the company a potential business partner/investment opportunity?
  • What is its financial performance?

You’re in good company

EMIS company reports are used extensively by the world’s biggest companies, financial institutions, professional service companies and universities to assess businesses in emerging markets.


company profiles

We have information on both public and private companies across 125 countries.



EMIS is the go-to information source on emerging market companies for the world’s most prestigious businesses.

Enterprise ACCESS

If you need regular and ongoing access to company information, you should consider a subscription to the full EMIS service.

EMIS company profiles are part of a larger information service where that combines company, industry and country data and analysis for over 125 emerging markets on a unique information platform.

Contact us to learn more about our business solutions.
Sign up to our newsletter

Make sure you’re not the last to know by getting the latest insights on emerging markets straight to your inbox.